BiotechTube

Livmarli Oral Product

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome

Trial Timeline

Sep 25, 2025 → Dec 22, 2030

NCT ID
NCT07290257

About Livmarli Oral Product

Livmarli Oral Product is a approved stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07290257. Target conditions include Alagille Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07290257ApprovedRecruiting

Competing Products

9 competing products in Alagille Syndrome

See all competitors
ProductCompanyStageHype Score
Odevixibat + PlaceboIpsenPhase 3
74
OdevixibatIpsenPhase 3
74
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
maralixibatMirum PharmaceuticalsPre-clinical
20
Livmarli + LivmarliMirum PharmaceuticalsPre-clinical
20
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
LUM001 (Maralixibat) + PlaceboMirum PharmaceuticalsPhase 2
49
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49

Other Products from Mirum Pharmaceuticals

MaralixibatPhase 3
74
Cholic AcidsPhase 3
74
MaralixibatPhase 3
74
Cholic acidPhase 3
74
Brelovitug 300 mg + Bulevirtide 2 mg and Brelovitug - 300 mgPhase 3
74